Is Firefly Neuroscience, Inc. (AIFF) a Buy, Sell, or Hold?
NASDAQ : AIFF
Firefly Neuroscience, Inc. — News
$1.135 USD
-$0.06 (-4.62%)
- Volume
- 946.6K
- Average Volume
- 230.58K
- Market Capitalization
- $17.71M
- P/E Ratio
- -1.67
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $3.63
- Year Low
- $0.62
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.82
| Source | Headline |
|---|---|
|
Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes
KENMORE, N.Y., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence ("AI") company advancing precision neuroscience, today announced a close to four-fold (291%) year-over-year increase in Transcranial Magnetic Stimulation (“TMS”) center customer clinical assessments using its U.S. Food and Drug Administration (“FDA”) 510(k)-cleared, AI-powered EEG/ERP platform, Evoke™. globenewswire.com - 2026-08-05 07:45:00 |
|
Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee's Recommendation Backs Broader Access to Key Neuroprotective Peptides
– FDA Advisory Committee voted to recommend easing compounding restrictions for six peptides, including Epitalon and Semax, late last week – globenewswire.com - 2026-07-28 07:50:00 |
|
Firefly's AI-Driven Evoke System Powers Discovery of Novel Electrophysiological Biomarker for PTSD
– Comes just weeks after Firefly confirmed its active public-private partnership with the U.S. Department of War – KENMORE, N.Y, June 02, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company advancing precision neuroscience, today announced the identification of a novel electrophysiological biomarker for Post-Traumatic Stress Disorder (“PTSD”) using brain scans collected on its FDA-510(k)-cleared Evoke System. The biomarker discovery emanates partly from Firefly's previously announced public-private partnership with the U.S. Department of War (“DoW”) to support the assessment and treatment of active-duty U.S. service members and veterans suffering from PTSD and/or Traumatic Brain Injury (“TBI”). globenewswire.com - 2026-06-02 07:40:00 |
